Elranatamab (PF-06863135) is a humanized bispecific antibody that targets BCMA (B-cell maturation antigen) on myeloma cells and CD3 on T cells. By targeting these molecules, Elranatamab activates T cells and directs them to induce a cytotoxic T cell response against myeloma cells. This compound is used in research for relapsed or refractory multiple myeloma.
CAS Nummer:
[2408850-14-4]
Target-Kategorie:
TNF
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten